When tested against each other, recombinant hepatitis B vaccines and plasma derived vaccines all produced high rates of seroprotection. (Levels were tested one month after the final dose.) The recombinant vaccine also demonstrated high protective efficacy in a variety of high risk populations, including neonates born to mothers that were carriers of hepatitis B. Recombinant hepatitis B has a tolerability profile similar to other hepatitis B vaccines, and it has a high level of protective efficacy. The recombinant vaccine is also promising because it offers flexibility in dosing schedules, and appeared to confer immunity for at least ten years (Keating & Noble, …show more content…
In a 1997 study published in the New England Journal of Medicine, a randomized double-blind trial with 180 participants suffering from rheumatoid arthritis did not reveal anything unsafe about recombinant TNF (Moreland, 1997). Three studies conducted in 2001 showed a remarkable safety profile for a different variation of recombinant human necrosis factor (binding protein-1). Intravenous, intramuscular, or subcutaneous injections were given to healthy volunteers. The safety profile was based on vital signs, hematology and blood chemistry, and antibodies to study drug and local tolerability (Trnchard-Lugan, Ho-Nguyen, Bilham, et. al.,